Defining the apoptotic and therapeutic activities of histone deacetylase inhibitors

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1028871

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

HDAC inhibitors (HDACi) are new chemotherapeutic drugs that kill tumors cells through a cell suicide process called apoptosis. We have used a mouse model of human blood cancers to show that these inhibitors can be used safely to severely limit the growth and spread of blood cancers. HDACi have the ability to inhibit multiple different target proteins (HDACs) and we aim to identify the key HDACs that cancer cells require to remain viable. Such information will lead to a more targeted or rational approach to chemotherapy using HDACi.

Funded Activity Details

Start Date: 01-01-2012

End Date: 01-01-2014

Funding Scheme: Project Grants

Funding Amount: $694,627.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

RNA interference | epigenetics | gene knockout | histone deacetylase | lymphoma | therapeutics

Related Links